Defining LRRK2-PD subsets based on olfactory function in the PPMI
Objective: A major goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical and biomarker defined disease subsets that may demonstrate differing disease…Celiac disease-related antibodies in Parkinson’s Disease patients: a case control study.
Objective: To compare anti-transglutaminase and antigliadin antibodies between Parkinson’s disease patients and healthy controls. A detailed gastrointestinal symptom investigation was studied and compared between patient…Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia
Objective: The aim of this study was to identify predictors of potential drug-drug interactions in patients suffering from Parkinson’s disease.The aim of this study was…VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS
Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS
Objective: To examine the efficacy and safety of LCIG in a ‘real world’ tertiary care center setting in patients with and without DBS. Background: Levodopa-Carbidopa…Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To assess the influence of a 6-month treatment with opicapone (OPC) on the costs for the care of Parkinson’s disease (PD) patients. Background: OPC…A French national multicentric prospective study of the 1-year impact of STN-DBS on speech in Parkinson’s disease: profile of progression and prognostic factors.
Objective: 1) To describe the evolution of speech in a large cohort of patients before and 1 year after STN-DBS. 2) To search for preoperative…Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients With Advanced Parkinson’s Disease
Objective: To evaluate real-world comparative effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) versus Deep Brain Stimulation (DBS) initiation on pill burden reduction in patients with Advanced…Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease
Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…Longitudinal 18F-PBR06 (TSPO) and Volumetric MR Imaging as Pharmacodynamic Endpoints for MSA – Ongoing Investigator Sponsored Trial of Verdiperstat
Objective: In multiple system atrophy (MSA) patients to: 1) evaluate 18F-PBR06 positron emission tomography (PET) for longitudinal assessment of 18-kilodalton-translocator protein (TSPO) binding; 2) assess…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 132
- Next Page »